contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


inside-information-nightingale-health-achieves-one-of-its-business-targets-for-this-financial-year-by-winning-contracts-in-medical-research-with-a-total-contract-value-of-at-least-eur-32-million

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.

Jep tuokin on mahdollista - taustalla voi olla myös aitoa innostusta teknologian hyödyistä ihmisten terveydelle (tämäkin on jo sellaisenaan jalo tarkoitusperä), halua auttaa toista kotimaista yhtiötä sen kansainvälistymisessä, hakea ulkomaisilta toimijoilta vastapalloon oppeja Terveystalon hyödynnettäväksi, tuoda Terveystalolle profiilia sektorin ajatusjohtajana jne. - ehkä jokin yhdistelmä näitä

Ehkä osa heidän sopimustaan? TT saa palvelun halvalla kun suostuu hieman sitä markkinoimaan.

Antti Luiro. Itse en ymmärrä mikä intressi Ilse Rauhaniemellä/Terveystalo on buustata Nightingalen testiä ulkomailla asti?

Lienee ihan paikan päällä. Jossain aiemmassa postauksessa tuumasi, että tämä itsenäisyyspäivä vietetään “vieraalla maalla”. Hieno homma !

Singaporessa on varmaan jo voitu kiertää mahdollisia asiakkaita/testien ostajia ja tehty ‘esimarkkinointia’ että tilaukset lähtisivät labran aukeamisen jälkeen rullaamaan  Diilit ovat kuitenkin käsittääkseni lähtökohtaisesti Innoquest Diagnosticsin ja ostajan välillä, joten voi hyvin olla ettei Nightingale pääsisi sellaisista tiedottamaan vaikka niitä tulisikin. Voin toki olla tässä väärässä.

Terveystalon Ilse Rauhaniemi on ensi viikolla Singaporessa (joko paikan päällä tai vähintään etäyhteyden välityksellä?) jakamassa kokemuksia Nightingalesta - kova juttu ja varmasti auttaa palvelun lanseerauksessa kunhan saadaan oikea kohderyhmä paikalle

Hieno homma. Muistan Sunan alkuvuoden Inderes haastattelussa maininneen että “tästä laboratorion aukeamiseen on hyvää aika tehdä myyntiä” tms. Mitähän kanavaa pitkin lienee nuo myynnit tapahtuneet? Saataisiko jopa jotain diilejä tiedoksi laboratorion aukeamisen yhteydessä

Nightingale Health

Company release, inside information25 April 2024 at 11:50 a.m. (EEST)Nightingale Health Plc ("Nightingale Health") has reached one of the business targets set for the financial year 1 July 2023...

Company release, inside information25 April 2024 at 11:50 a.m. (EEST)Nightingale Health Plc ("Nightingale Health") has reached one of the business targets set for the financial year 1 July 2023 - 30 June 2024 by winning contracts in medical research with a total contract value of at least EUR 3.2 million."The demand for our services has been strong during the financial year, resulting in achieving this business target well in time before the end of the financial year", comments Teemu Suna, Nightingale Health's CEO and Founder.The timeline in which the contract value from these contracts is recognized as revenue depends on the blood sample delivery and analysis schedules.For further information, please contact:Teemu Suna, CEO ir@nightingalehealth.comCertified advisor:Oaklins Merasco Ltd, tel. +358 9 6129 670About Nightingale HealthNightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it's also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the First North Growth Market Finland marketplace. Read more: <a href="https://nightingalehealth.com">https://nightingalehealth.com</a>

Inside information: Nightingale Health achieves one of its business targets for this financial year by winning contracts in medical research with a total contract value of at least EUR 3.2 million

Beställ vårt nyhetsbrev — inget användarkonto krävs!